2025-11-30 - Analysis Report
Okay, here's a comprehensive analysis of Tempus AI (TEM) based on the provided data:

**1) Return Rate Analysis**

*   **Simple Numbers:**
    *   TEM Cumulative Return: 40.99%
    *   S&P 500 (VOO) Cumulative Return: 31.14%
    *   Divergence: 12.6
    *   Relative Divergence: 46.2

*   **Analysis:**
    *   **Company Overview:** Tempus AI Inc. is likely a company leveraging AI within the healthcare or biotechnology sector.
    *   TEM has outperformed the S&P 500 over the observed period.
    *   The divergence of 12.6 means TEM has a higher cumulative return by 12.6% as compared to the S&P 500.
    *   The relative divergence of 46.2 suggests that the current divergence is in the middle of its historical range, indicating it's not exceptionally high or low compared to its past performance versus the S&P 500.
    *   **Alpha, Beta Analysis Table Interpretation:**
        *   **CAGR (Compound Annual Growth Rate):** 41.0% indicates a strong average annual growth rate from 2023-2025.
        *   **MDD (Maximum Drawdown):** 76.7% is a very high MDD, implying significant potential for losses and high volatility.
        *   **Alpha:** 11.0% positive alpha suggests TEM has outperformed its benchmark (likely the S&P 500) by 11.0% annually on a risk-adjusted basis.
        *   **Beta:** 0.3 indicates TEM is significantly less volatile than the market. A beta less than 1 means the price is less responsive to market movements.
        *   **Cap(B):** 13.9 means the company has a capitalization of 13.9 Billion.

**2) Recent Stock Price Fluctuations**

*   **Simple Numbers:**
    *   Current Close: 77.93
    *   Previous Close: 77.21
    *   Change: 0.93
    *   5-day SMA: 75.67
    *   20-day SMA: 74.19
    *   60-day SMA: 83.00

*   **Analysis:**
    *   The stock price closed higher than its previous close, showing positive momentum.
    *   The 5-day and 20-day SMAs are below the current price, suggesting a short-term upward trend.
    *   The 60-day SMA is significantly higher than the current price, indicating that the price has recently dropped below its medium-term average.

**3) Technical Indicators**

*   **Simple Numbers:**
    *   MRI: 0.9 (High Investment Recommended)
    *   RSI: 62.72
    *   PPO: 1.67
    *   Hybrid Signal: cash_0%_Buy 100% of cash (28 shares - Very Safe - MRI:0.90)
    *   Recent Relative Divergence Change: 3.8 (+) (Short-term increase)
    *   Expected Return (%): NaN

*   **Analysis:**
    *   **MRI:** A high MRI score suggests the current market conditions are favorable for investment in this stock.
    *   **RSI:** An RSI of 62.72 indicates that the stock is approaching overbought conditions but isn't there yet.
    *   **PPO:** A positive PPO suggests the short-term moving average is above the long-term moving average, indicating an uptrend.
    *   **Hybrid Signal:** The signal recommends a strong buy, allocating 100% of available cash to purchase 28 shares, reflecting high confidence.
    *   **Recent Relative Divergence Change:** The positive change in relative divergence over the past 20 days confirms a recent upward trend in performance compared to the S&P 500.
    *   **Expected Return:** The NaN (Not a Number) for expected return is problematic and requires investigation.  This could be due to data errors, model limitations, or the relatively short history of the stock (being recently IPO'd).

**4) Recent News & Significant Events**

*   **Key Headlines:**
    *   **FDA Clearance & Earnings Report:**  News focuses on opinions related to these crucial factors.
    *   **Q3 Earnings Release Analysis:** Analysts are actively evaluating the company's performance.
    *   **Buying Opportunity:**  Some analysts (Seeking Alpha) see recent weakness as a buying opportunity.
    *   **Price Target Increase:**  Yahoo Finance reports a $110 price target based on AI adoption.
    *   **Cathie Wood Purchase:**  A prominent investor buying shares could signal confidence in the company.
    *   **Institutional Investment:** Legal & General Group Plc purchasing shares suggests institutional interest.

*   **Analysis:** The news flow is generally positive, with a focus on growth drivers (AI adoption), analyst upgrades, and institutional investment.

**4-2) Analyst Opinions**

*   **Consensus:**
    *   Overall consensus leans towards a "Buy" rating.
    *   Average rating of 2.14 reflects a generally positive outlook.
    *   12 analysts providing opinions suggests reasonable coverage.
    *   Target Price: Average target of $91.00, with a high of $105.00, indicates potential upside.

*   **Recent Rating Changes:** Absence of rating changes in the last period.

**5) Comprehensive Analysis**

*   **Summary:**  Tempus AI (TEM) is a potentially high-growth company in the AI-driven healthcare sector.  It has outperformed the S&P 500 recently.  The technical indicators are mostly positive, with a strong buy signal. Analyst sentiment is generally bullish, with a "Buy" consensus and a price target significantly above the current price.  News flow highlights growth opportunities and institutional interest.

*   **Key Considerations:**
    *   **Volatility:** The high MDD (76.7%) in the Alpha/Beta analysis means that while there is growth potential, there is also significant risk of loss.
    *   **Expected Return:** The missing expected return data point needs to be resolved to make a more informed long-term investment decision.
    *   **New Company:** Being a relatively new public company, TEM will have less historical data than most stocks, so analyses should be interpreted with caution.
    *   **Sector Risk:** AI and healthcare are dynamic sectors. FDA clearance, regulation, and competition will all be key factors to watch.

*   **Overall Recommendation:**  Based on the provided information, TEM appears to be a potentially attractive investment, but only for investors with a high-risk tolerance and a thorough understanding of the company's business and the industry it operates in. Resolve the missing "Expected Return" data point, and conduct further due diligence before investing.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.